Loading...
•
Dec 31, 2025
OptimizeRx Q4 2025 Earnings Report
OptimizeRx Q4 2025 Earnings Report
Key Takeaways
OptimizeRx delivered a strong fourth quarter with record net income and adjusted EBITDA, despite flat year-over-year revenue. The company successfully achieved 'Rule of 40' status for the full year 2025 and authorized a new $10 million share repurchase program.
Achieved record Q4 GAAP net income of $5.0 million and record Adjusted EBITDA of $12.0 million.
Reached 'Rule of 40' benchmark for the full year 2025 with 19% revenue growth and 22% Adjusted EBITDA margins.
Board of Directors authorized a $10 million share repurchase program effective March 12, 2026.
Updated 2026 revenue guidance to $109-$114 million, reflecting caution due to market volatility and MFN pricing uncertainty.
Forward Guidance
OptimizeRx is providing guidance for the fiscal year 2026, balancing strong underlying demand against near-term market volatility.
Positive Outlook
- Targeting full year 2026 revenue between $109 million and $114 million
- Expected Adjusted EBITDA between $21 million and $25 million
- Confidence in underlying demand trends and solid network engagement
- Ongoing mission-critical role in reducing script abandonment and improving brand visibility
- Anticipated benefits from AI enabling customers to reallocate budgets toward reach and execution
Challenges Ahead
- Increased market volatility observed
- Uncertainty surrounding Most Favored Nation (MFN) pricing
- Customers taking a more measured approach to discretionary spending
- Shortened contract durations from some customers
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...